The Europe amniotic membrane market growth analysis includes the assessment of France, Italy, Germany, Poland, the United Kingdom, Belgium, Nordic Countries, and Rest of Europe. Amniotic membrane transplants are on the rise in the United Kingdom, given their benefits in treating conjunctiva, corneal, and scleral disorders. The amniotic membrane treatments are successfully done under the United Kingdom standards and the European Union regulations. Also, the UK market growth is benefitted from the availability of suture-less amniotic membrane products like ProKera (BioTissue Inc) and Omnigen (NuVision Biotherapies Limited). In addition, the domestic market players have implemented successful strategic developments. For instance, NuVision Biotherapies Limited has continuously been engaged in developing the amniotic membrane, collaborating with government organizations. 

In France, the growing awareness regarding amniotic membrane (AM), particularly in terms of ocular surface reconstruction, drives market growth opportunities. Also, AM is widely used for treating persistent epithelial defects and non-healing corneal ulcers, bullous keratopathy, descemetoceles, and corneal perforations. Additionally, the increasing number of eye disorders contributes to market growth alongside a significant population with unmet eye care needs. Besides, the country houses several human tissue banks like Saint Louis Hospital that preserve AM from donors. 

The Europe amniotic membrane market scope includes product, application, and end-user. The application segment includes surgical wounds, ophthalmology, and other applications.

The use of amniotic membranes for repairs and injuries, particularly burns, has displayed significant results. Also, AM has proved to be a versatile biologic dressing. Wounds unresponsive to usual therapeutic measures respond to AM application. As a result, AM dressings are increasingly used in the care of complicated wounds. Furthermore, AM has anti-scarring properties that minimize scar tissue formation. 

The other applications of AM include acute & chronic wounds, orthopedic surgeries, and burns. Chronic injuries are a major concern. For instance, diabetic foot ulcer (DFU) is a primary complication of diabetes. Almost 25% of the total diabetic population develops DFU. In addition, AM has been employed for several other applications, including disorders associated with the oral cavity, stomach, skin, head & neck, larynx, etc. Moreover, there has been a growing interest in amniotic membranes in recent years for the treatment of ocular surface disorders due to their intrinsic properties. 

Some of the leading players in the Europe amniotic membrane market include Integra LifeSciences, Labtician Ophthalmics Inc, MiMedx Group Inc, Human Regenerative Technologies LLC, etc.

Integra LifeSciences is a global leader in medical technology. It offers advanced solutions in general surgery, reconstructive surgery, orthopedic extremity surgery, and neurosurgery advanced wound management. The company’s product portfolio includes solutions for the management of multiple disease states, including hemorrhagic stroke, hydrocephalus, traumatic brain injury, etc. Additionally, it offers innovative healthcare solutions through 50 offices in over 130 countries, with headquarters in Princeton, New Jersey, United States.

One of its key products, Integra Bilayer Wound Matrix, is an enhanced wound care device with a porous matrix of cross-linked bovine tendon collagen. It facilitates an ideal environment to supplement cellular repopulation and revascularization processes central to wound healing.